ORCID

Abstract

AbstractThe COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication is observed in animals when the drug is administered either beginning 12 h before or 12 h following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients.

DOI

10.1038/s41467-021-22580-8

Publication Date

2021-02-18

Publication Title

Nature Communications

Volume

12

Issue

1

ISSN

2041-1723

Embargo Period

2021-08-14

Organisational Unit

School of Biomedical Sciences

Share

COinS